:: Volume 21, Issue 4 (Bimonthly 2017) ::
Feyz 2017, 21(4): 376-382 Back to browse issues page
Analysis of rs7526084 polymorphism in 3′ downstream of the sestrin 2 gene as an informative marker for molecular diagnosis of kidney stone disease
Elham Parvasi , Mahboobeh Nasiri , Dariush Irani
Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, I. R. Iran. , nasiri@iaua.ac.ir
Abstract:   (2982 Views)
Background: Kidney stone disease is one of the most common disorders of urinary tract, manifesting with high clinical and genetic heterogeneity in population. Sestrin 2 is involved in many essential processes, especially oxidative and genotoxic stress. Regarding the importance of oxidative stress pathway deregulation in systemic diseases such as kidney disorders, this study was conducted to investigate the association between rs7526084 3′ downstream polymorphism of the sestrin 2 gene and risk of kidney stone in south Iranian patients.
Materials and Methods: In this case-control study, 150 patients with kidney stone disease and 180 age- and gender-matched healthy individuals were participated from March to December 2015. Genotyping of the rs7526084 polymorphism was performed using the T-ARMS PCR method.
Results: Frequency of the G allele was higher in controls than in cases, and a reduced risk of the disease was shown in the presence of this allele (OR: 0.66, 95%CI: 0.48-0.91, P=0.01). Also, the risk of the disease was reduced in the presence of heterozygote CG (OR: 0.49, 95%CI: 0.30-0.80, P=0.004) and homozygote GG (OR: 0.47, 95%CI: 0.23-0.96, P=0.04) genotypes. Under the dominant genetic model for the G allele (GG+GC vs. CC), this allele significantly reduced the risk of the disease (OR: 0.49, 95%CI: 0.31- 0.78, P= 0.002).
Conclusion: Reduced risk of kidney stone in the presence of the G allele of the sestrin 2 gene polymorphism might provide the evidence in favor of the involvement of the oxidative stress pathway in the pathogenesis of kidney stone disease.
Keywords: Kidney stone disease, Oxidative stress, Sestrin 2, Polymorphism
Full-Text [PDF 332 kb]   (1444 Downloads)    
Type of Study: Research | Subject: medicine, paraclinic
Received: 2017/03/15 | Revised: 2017/10/7 | Accepted: 2017/07/4 | Published: 2017/10/7
References
1. Khan AS, Rai ME, Gandapur PA, Shah AH, Hussain AA, Siddiq M. Epidemiological risk factors and composition of urinary stones in Riyadh Saudi Arabia. J Ayub Med Coll Abbottabad 2004; 16(3): 56-8.
2. Pourmand Gh, Pourmand B. Epidemiology of stone disease in Iran. Urolithiasis 2012; 85-7.
3. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010; 12(2-3): e86.
4. Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol 2009; 24(12): 2321-32.
5. Safarinejad MR. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. Urol Res 2007; 35(2): 73–82.
6. Ozbek E. Induction of oxidative stress in kidney. Int J nephrol 2012; 2012: 465897.
7. Tamadon MR, Nassaji M, Ghorbani R. Cigarette Smoking and Nephrolitiasis in Adult Individuals. Nephrourol Mon 2013; 5(1): 702-5.
8. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408(6809): 239‐47.
9. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004; 58(1): 39-4612.
10. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84(21-22): 705‐12.
11. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative Stress and Antioxidant Defense. World Allergy Organ J 2012; 5(1): 9-19.
12. Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, et al. Identification of a novel stress‐ responsive gene Hi95 involved in regulation of cell viability. Oncogene 2002; 21(39): 6017-6031.
13. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53‐regulated sestrins, homologs of bacterial AhpD. Science 2004; 304 (5670): 596-600.
14. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL, et al. Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 2009; 8(10): 1571–6.
15. Peeters H, Debeer P, Bairoch A, Wilquet V, Huysmans C, Parthoens E, et al. PA26 is a candidate gene for heterotaxia in humans: Identification of a novel PA26-related gene family in human and mouse. Hum Genet 2003; 112(5-6): 573-80.
16. Yang Y, Cuevas S, Yang S, Villar VA, Escano C, Asico L, et al. Sestrin2 Decreases Renal Oxidative Stress, Lowers Blood Pressure, and Mediates Dopamine D2 Receptor–Induced Inhibition of Reactive Oxygen Species Production. Hypertension 2014; 64(4): 825-32.
17. Kuersten S, Goodwin EB. The power of the 3'UTR: translational control and development. Nature 2003; 4(8): 626-37.
18. Jahangirizade K, Nasiri M, Asmarian NS. Association of rs1042658 Polymorphism of the CSF3 Gene with the Susceptibility of Recurrent Pregnancy Loss in Women of Fars Province. Arak Med Uni J 2016; 19(106): 23-31.
19. Li CY, Deng YL, Sun BH. Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis. Urol Res 2009; 37(4): 211-20.
20. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8(2): 75-88.
21. Essler S, Dehne N, Brüne B. Role of sestrin2 in peroxide signaling in macrophages. FEBS Lett 2009; 583(21): 3531–5.
22. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4(4): 804-11.
23. Zhou D, Zhan C, Zhong Q, Li S. Upregulation of sestrin-2 expression via P53 protects against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity. J Mol Neurosci 2013; 51(3): 967-75.
24. Oberley TD, Verwiebe E, Zhong W, Kang SW, Rhee SG. Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med 2001; 30(4): 412-24.
25. Simzar S, Ellyin R, Shau H, Sarafian TA. Contrasting antioxidant and cytotoxic effects of peroxiredoxin I and II in PC12 and NIH3T3 cells. Neurochem Res 2000; 25(12): 1613-21.
26. Ichimiya S, Davis JG, O'Rourke DM, Katsumata M, Greene MI. Urine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol 1997; 16(3): 311-21.
27. Yao J, Taylor M, Davey F, Ren Y, Aiton J, Coote P, et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 2007; 35(2): 377-82.
28. Hattori F, Murayama N, Noshita T, Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 2003; 86(4): 860-8.
29. Boulos S, Meloni BP, Arthur PG, Bojarski C, Knuckey NW. Peroxiredoxin 2 overexpression protects cortical neuronal cultures from ischemic and oxidative injury but not glutamate excitotoxicity, whereas Cu/Zn superoxide dismutase 1 overexpression protects only against oxidative injury. J Neurosci Res 2007; 85(14): 3089-97.
30. Wu CL, Su TC, Chang CC, Kor CT, Chang CH, Yang TH, et al. Tubular Peroxiredoxin 3 as a Predictor of Renal Recovery from Acute Tubular Necrosis in Patients with Chronic Kidney Disease. Sci Rep 2017; 7: 43589.
31. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2001; 52(1–2): 35-41.
32. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 2008; 11(4): 476–87.
33. Soriano FX, Papadia S, Bell KF, Hardingham GE. Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. Epigenetics 2009; 4(3): 152-8.
34. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128(4): 693–705.

XML   Persian Abstract   Print

Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
Volume 21, Issue 4 (Bimonthly 2017) Back to browse issues page